trending Market Intelligence /marketintelligence/en/news-insights/trending/u6x_fudni_wba7i9peuuvg2 content esgSubNav
In This List

Medical Prognosis Institute shareholders approve Oncology Venture Sweden merger

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Medical Prognosis Institute shareholders approve Oncology Venture Sweden merger

Shareholders of Denmark-based Medical Prognosis Institute A/S voted in favor of the company's merger with Oncology Venture Sweden AB.

Under the deal, Oncology Venture stockholders will exchange each share they hold for 1.8524 Medical Prognosis Institute shares. They will own about 51.3% of the merged entity.

Medical Prognosis Institute is a precision medicine company that develops drugs to treat cancer using its drug response predictor technology. Oncology Venture Sweden develops anticancer drugs.